American Society for Reproductive Medicine, Birmingham, Alabama.
Fertil Steril. 2018 Aug;110(3):387-400. doi: 10.1016/j.fertnstert.2018.05.009.
Adjuvant immunotherapy treatments in in vitro fertilization (IVF) aim to improve the outcome of assisted reproductive technology (ART) in both the general ART population as well as subgroups such as patients with recurrent miscarriage or implantation failure. The purpose of this guideline is to evaluate the role of immunomodulating therapy in ART. Unfortunately, many of the evaluated therapies lack robust evidence from well-designed adequately powered randomized controlled trials to support their use. Immunotherapies reviewed in the present document are either not associated with improved live-birth outcome in IVF or have been insufficiently studied to make definitive recommendations.
辅助免疫治疗在体外受精（IVF）中旨在改善辅助生殖技术（ART）的结果，包括一般 ART 人群以及反复流产或着床失败等亚组患者。本指南的目的是评估免疫调节治疗在 ART 中的作用。不幸的是，许多评估的治疗方法缺乏来自精心设计的充分有力的随机对照试验的可靠证据来支持其使用。本文中回顾的免疫疗法要么与 IVF 中活产结局的改善无关，要么研究不足，无法做出明确的推荐。
